Drug Patents owned by Urovant
1. List of Gemtesa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8653260 | UROVANT | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
Apr, 2029
(5 years from now) | |
| US8247415 | UROVANT | Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists |
Dec, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Dec 23, 2025 |
Drugs and Companies using VIBEGRON ingredient
NCE-1 date: 2024-12-23
Market Authorisation Date: 23 December, 2020
Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency
Dosage: TABLET;ORAL
GEMTESA family patents
8
United States
3
Korea, Republic of
3
Japan
2
Dominican Republic
2
Costa Rica
2
China
1
Colombia
1
Ecuador
1
Australia
1
EA
1
El Salvador
1
Israel
1
Croatia
1
Canada
1
New Zealand
1
Denmark
1
Honduras
1
Spain
1
Tunisia
1
Peru
1
Austria
1
Nicaragua
1
Chile
1
ME
1
Cyprus
1
Singapore
1
Portugal
1
Ukraine
1
Poland
1
Morocco
1
Hong Kong
1
Slovenia
1
Mexico
1
Georgia
1
Argentina
1
RS
1
Brazil
1
South Africa
1
Taiwan
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic